大剂量安吖啶（AMSA）治疗复发和难治性成人急性非淋巴细胞白血病。一项II期研究。

High-dose amsacrine (AMSA) therapy of relapsed and refractory adult acute nonlymphocytic leukemia. A phase II study.

作者信息

Cassileth P A, Lyman G H, Bennett J M, Glick J H, Oken M M

出版信息

Am J Clin Oncol. 1984 Aug;7(4):361-3. doi: 10.1097/00000421-198408000-00013.

DOI:10.1097/00000421-198408000-00013

Abstract

Amsacrine (AMSA) has been shown to be an effective therapeutic agent in the treatment of adult acute nonlymphocytic leukemia (ANLL). The Eastern Cooperative Oncology Group studied the efficacy and toxicity of high-dose amsacrine (200 mg/m2/day for 5 days) in 38 adult patients with refractory and relapsed ANLL. The complete remission rate was low (8%). This dose level of amsacrine caused severe mucositis in 24% of patients and marked liver function abnormalities in 11%. Seizures did not occur, and two reversible cardiac events were not clearly attributable to amsacrine administration. Escalation of amsacrine beyond currently recommended total doses of 600-750 mg/m2 is unlikely to be of benefit.

摘要

安吖啶（AMSA）已被证明是治疗成人急性非淋巴细胞白血病（ANLL）的一种有效治疗药物。东部肿瘤协作组研究了大剂量安吖啶（200mg/m²/天，共5天）对38例难治性和复发性ANLL成年患者的疗效和毒性。完全缓解率较低（8%）。这个剂量水平的安吖啶导致24%的患者出现严重黏膜炎，11%的患者出现明显肝功能异常。未发生癫痫发作，有两例可逆性心脏事件不能明确归因于安吖啶给药。将安吖啶剂量增至超过目前推荐的600 - 750mg/m²的总剂量不太可能有益。